19 news items
FDA adverse event data shows over 455 reports linked to compounded semaglutide and 320 tied to compounded tirzepatide, many involving hospitalisation due to dosing errors from multi-dose vials. A 2026…
South African health regulators have issued a Class I, Type A recall of iDexis semaglutide and tirzepatide products and warned doctors and pharmacists that continued prescribing or dispensing could result…
South Africa's three major health regulatory bodies issued a joint Class I, Type A recall — the most serious safety alert level — of iDexis semaglutide and tirzepatide products, warning…
Judges on the US Court of Appeals for the Fifth Circuit questioned the legal foundations of the FDA's compounding ban during oral arguments that observers described as unusually pointed. The…
As the legal and regulatory battle over compounded GLP-1s intensifies, the FDA has been building a parallel public health case based on real-world harm data. The numbers are striking: as…
On 9 February 2026, Novo Nordisk filed a federal patent infringement lawsuit against Hims & Hers Health, the publicly traded telehealth company, alleging it had continued to mass-compound injectable semaglutide…
South Africa does not have a compounding industry for GLP-1 medications at the scale that existed in the United States during the shortage period. The Medicines and Related Substances Act…
Register free to read every article, receive our weekly digest and submit questions to our expert panel.
Already registered? Sign in here
